BBC

Virtus LifeSci Biotech Clinical Trials ETF

$32.34

+0.00%

Market closed. Last update: 10:51 PM ET

📎 Investment Objective

The Virtus LifeSci Biotech Clinical Trials ETF (BBC) seeks to provide investment results that closely correspond, before fees and expenses, to the performance of the LifeSci Biotechnology Clinical Trials Index.

Overview

ETF tracking Virtus LifeSci Biotech Clinical Trials ETF

Category Technology

Issuer Other

Inception Date 2017-09-01

Market Cap $21.0M

Average Volume N/A

Dividend Yield 0.74%

52-Week Range $14.14 - $32.34

VWAP $32.72

Performance

Loading performance data...

Price Chart

Investment Summary

📎 Investment Objective

🎯 Investment Strategy

The ETF invests in a portfolio of companies that are primarily engaged in the clinical trials phase of the drug development process. The fund seeks to track the LifeSci Biotechnology Clinical Trials Index, which is designed to measure the performance of biotechnology companies that have one or more drug candidates in the clinical trials phase of development.

✨ Key Features

Focuses on biotechnology companies in the clinical trials stage of drug development
Provides exposure to the potentially high-growth but high-risk biotech sector
Passively managed to track the LifeSci Biotechnology Clinical Trials Index
Low expense ratio of 0.00%

⚠️ Primary Risks

High volatility and risk due to the speculative nature of clinical-stage biotechnology companies
Concentration risk as the fund is focused on a narrow segment of the biotech industry
Lack of performance history as the fund is relatively new with no track record
Liquidity risk due to the potentially low trading volume of the underlying stocks

👤 Best For

The Virtus LifeSci Biotech Clinical Trials ETF may be suitable for investors with a high risk tolerance who are seeking exposure to the potentially high-growth but volatile biotechnology sector, particularly companies in the clinical trials stage of drug development. This ETF is best suited for long-term, growth-oriented investors who can withstand the significant volatility and risks associated with the biotech industry.